Drug Profile


Alternative Names: BAY-853934; HIF-PH; HIF-PH inhibitor - Bayer; Hypoxia-inducible factor-prolyl hydroxylase inhibitor - Bayer

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Antianaemics; Morpholines; Pyrazoles; Pyrazolones; Pyrimidines; Small molecules; Triazoles
  • Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Anaemia

Most Recent Events

  • 01 Jun 2016 Bayer completes a phase I pharmacokinetics trial in subjects with Renal impairment in Germany (NCT02312973)
  • 01 Dec 2015 Bayer completes the phase II DIALOGUE4 trial in Anaemia (Maintenance therapy, associated with chronic renal failure) in USA and Japan (NCT01975818)
  • 15 Oct 2015 Bayer completes enrolment in the phase II DIALOGUE 4 trial for Anaemia (Maintenance therapy, associated with chronic renal failure) in USA and Japan (NCT01975818)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top